• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by ClearPoint Neuro Inc.

    9/4/25 4:05:42 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care
    Get the next $CLPT alert in real time by email
    S-8 1 clpt-20250904.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on September 4, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

    CLEARPOINT NEURO, INC.

    (Exact name of registrant as specified in its charter)

    Delaware

    58-2394628

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

    120 S. Sierra Ave., Suite 100

    Solana Beach, California

    92075

    (Address of principal executive offices)

    (Zip Code)

     

    ClearPoint Neuro, Inc. Amended and Restated 2021 Employee Stock Purchase Plan

    ClearPoint Neuro, Inc. Sixth Amended and Restated 2013 Incentive Compensation Plan

    (Full title of the plans)

    Ellisa Cholapranee

    General Counsel and Secretary

    120 S. Sierra Ave., Suite 100

    Solana Beach, California 92075

    (Name and address of agent for service)

    (888) 287-9109

    (Telephone number, including area code, of agent for service)

    With copies to:

    John Tishler, Esq.
    Sheppard, Mullin, Richter & Hampton LLP
    12275 El Camino Real, Suite 100
    San Diego, CA, 92130-4092
    (858) 720-8900

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     


     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

    Emerging growth company

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    EXPLANATORY NOTE

    ClearPoint Neuro, Inc. (the “Company”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering additional shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), under each of the ClearPoint Neuro, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (the “ESPP”) and the ClearPoint Neuro, Inc. Sixth Amended and Restated 2013 Incentive Compensation Plan (the “Incentive Compensation Plan”).

     

    This Registration Statement relates to the following currently effective registration statements on Form S-8 (collectively, the “Existing S-8s”) filed with the Securities and Exchange Commission (the “SEC”):

     

    •
    Registration Statement No. 333-279454, filed with the SEC on May 16, 2024, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated;

     

    •
    Registration Statement No. 333-265349, filed with the SEC on June 1, 2022, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated;

     

    •
    Registration Statement No. 333-256789, filed with the SEC on June 4, 2021, relating to the ClearPoint Neuro, Inc. Amended and Restated 2021 Employee Stock Purchase Plan;

     

    •
    Registration Statement No. 333-238907, filed with the SEC on June 3, 2020, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated;

     

    •
    Registration Statement No. 333-220783, filed with the SEC on October 3, 2017, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated;

     

    •
    Registration Statement No. 333-206432, filed with the SEC on August 17, 2015, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated; and

     

    •
    Registration Statement No. 333-191908, filed with the SEC on October 25, 2013, relating to the ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan, as amended and restated.

     

    This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities. Pursuant to General Instruction E of Form S-8, the contents of the Existing S-8s are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement.

    -1-

     

     

     


     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Company with the SEC pursuant to the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

     

    ●

    The Company’s definitive proxy statement on Schedule 14A, filed with the Commission on April 9, 2025;

     

     

     

    ●

    The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 26, 2025;

     

    ●

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the SEC on May 13, 2025;

     

     

     

     

    ●

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the SEC on August 12, 2025;

     

     

     

    ●

    The Company’s Current Reports on Form 8-K (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed with the SEC on each of May 12, 2025, May 19, 2025, May 23, 2025 and June 17, 2025; and

    ●

    The description of the Company’s Common Stock, contained in Exhibit 4.4 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on March 12, 2024, including any amendments or reports filed for the purpose of updating such description.

    In addition, all other reports and documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

    Item 8. Exhibits.

    Exhibit Number

    Description

    4.1

    Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (Previously filed as, and incorporated herein by reference to, Exhibit 3.1 to our quarterly report on Form 10-Q, filed on May 11, 2012; File No. 000-54575).

    4.2

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (Previously filed as, and incorporated herein by reference to, Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 8, 2015).

    4.3

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (Previously filed with, and incorporated herein by reference to, Exhibit 3.3 to the Company's Registration Statement on Form S-1 filed on August 2, 2016).

     


     

    4.4

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (Previously filed with, and incorporated herein by reference to, Exhibit 3.1 to the Company's Current Report on Form 8-K filed on February 12, 2020).

    4.5

     

    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (Previously filed with, and incorporated herein by reference to, Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 25, 2023).

    4.6

     

    Fourth Amended and Restated Bylaws of ClearPoint Neuro, Inc. (Previously filed with, and incorporated herein by reference to, Exhibit 3.1 to the Company's Current Report on Form 8-K filed on December 14, 2022).

    5.1*

    Opinion of Sheppard, Mullin, Richter & Hampton LLP

    10.1

     

    ClearPoint Neuro, Inc. Sixth Amended and Restated 2013 Incentive Compensation Plan (Previously filed with, and incorporated herein by reference to, Exhibit 10.1 to the Company's Current Report on Form 8-K filed on May 23, 2025).

    10.2

    ClearPoint Neuro, Inc. Amended and Restated 2021 Employee Stock Purchase Plan (Previously filed with, and incorporated herein by reference to, Appendix A to our Definitive Proxy Statement on Schedule 14A, filed on April 9, 2025, File No. 001-34822).

    23.1*

    Consent of Cherry Bekaert LLP

    23.2*

    Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1)

    24.1*

    Power of Attorney (included as part of the signature page to this Registration Statement).

    107*

    Filing Fee Table

    *

    Filed herewith.

    -2-

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Solana Beach, State of California, on the 4th day of September, 2025.

         CLEARPOINT NEURO, INC.

     

     

    By:  /s/ Joseph M. Burnett

    Joseph M. Burnett

    Chief Executive Officer and President

    (Principal Executive Officer)

     

    POWER OF ATTORNEY

    Each person whose individual signature appears below hereby authorizes and appoints Joseph M. Burnett and Danilo D’Alessandro and each of them, with full power of substitution and resubstitution and full power to act without the other, as his true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file, any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

    SIGNATURE

    TITLE

    DATE

    /s/ Joseph M. Burnett

    President, and Chief Executive Officer and Director

    September 4, 2025

    Joseph M. Burnett

    (Principal Executive Officer)

     

     

    /s/ Danilo D'Alessandro

    Chief Financial Officer

    September 4, 2025

    Danilo D’Alessandro

    (Principal Financial and Accounting Officer)

     

     

    /s/ R. John Fletcher

    Chairman and Director

    September 4, 2025

    R. John Fletcher

     

     

    /s/ Lynnette C. Fallon

    Director

    September 4, 2025

    Lynnette C. Fallon

     

     

    /s/ Pascal E.R. Girin

    Director

    September 4, 2025

    Pascal E.R. Girin

     

     

    /s/ B. Kristine Johnson

    Director

    September 4, 2025

    B. Kristine Johnson

     

     

     

     

     

     

    /s/ Matthew B. Klein

    Director

    September 4, 2025

     


     

    Matthew B. Klein

     

     

     

     

     

     

    /s/ Linda M. Liau

    Director

    September 4, 2025

    Linda M. Liau

     

     

     

     

     

     

    /s/ Timothy T. Richards

    Director

    September 4, 2025

    Timothy T. Richards

     

    -3-

     

     


    Get the next $CLPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLPT

    DatePrice TargetRatingAnalyst
    7/25/2024$10.00Buy
    B. Riley Securities
    10/24/2023$8.00Buy
    Stifel
    2/16/2023$14.00Buy
    B. Riley Securities
    4/5/2022$15.00Buy
    B. Riley Securities
    More analyst ratings

    $CLPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain

    Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the SmartFlow Neuro Cannula using the De Novo pathway. The SmartFlow Neuro Cannula is intended for intraputaminal administration of PTC Therapeutics' gene therapy KEBILIDI™ (eladocagene exuparvovec-tneq) for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This signifies th

    11/13/24 1:20:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro Reports Third Quarter 2024 Results

    Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.Third Quarter HighlightsReported quarterly revenue of $8.1 million, a 41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of $2.9 million, a 53% year-over-year increase;Overall product revenue, inc

    11/7/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

    President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguards of Healthcare Podcast TodaySOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguards of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found HERE.Healthcare Conferences with Participation of ClearPoint Neuro Management Include:UBS Global Healthcare Conference in

    10/31/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer D'Alessandro Danilo was granted 376 shares, increasing direct ownership by 0.57% to 66,368 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    7/2/25 5:13:49 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Chief Business Officer Stigall L. Jeremy was granted 1,608 shares, increasing direct ownership by 2% to 72,355 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    7/2/25 5:11:30 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Sabra Mazin was granted 361 shares, increasing direct ownership by 0.71% to 51,564 units (SEC Form 4)

    4 - ClearPoint Neuro, Inc. (0001285550) (Issuer)

    7/2/25 5:08:46 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CLPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $10.00

    7/25/24 8:27:37 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Stifel initiated coverage on ClearPoint Neuro with a new price target

    Stifel initiated coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $8.00

    10/24/23 6:18:03 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on ClearPoint Neuro with a new price target

    B. Riley Securities resumed coverage of ClearPoint Neuro with a rating of Buy and set a new price target of $14.00

    2/16/23 7:44:43 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Financials

    Live finance-specific insights

    View All

    ClearPoint Neuro to Announce Third Quarter 2024 Results November 7, 2024

    SOLANA BEACH, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 third quarter on Thursday, November 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 third quarter on Thursday, November 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or a

    10/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce Second Quarter 2024 Results August 7, 2024

    SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 second quarter on Wednesday, August 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 second quarter on Wednesday, August 7th at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or

    7/17/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024

    SOLANA BEACH, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2024 first quarter on Tuesday, May 7th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2024 first quarter on Tuesday, May 7th, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here. Investors and analysts who would like to participate in the conference call via telephone may do so at (877) 407-9034, or at (201

    4/23/24 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    SEC Filings

    View All

    SEC Form S-8 filed by ClearPoint Neuro Inc.

    S-8 - ClearPoint Neuro, Inc. (0001285550) (Filer)

    9/4/25 4:05:42 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by ClearPoint Neuro Inc.

    10-Q - ClearPoint Neuro, Inc. (0001285550) (Filer)

    8/12/25 5:19:06 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ClearPoint Neuro, Inc. (0001285550) (Filer)

    8/12/25 4:05:43 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    $CLPT
    Leadership Updates

    Live Leadership Updates

    View All

    ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

    SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to have Mazin join our team and bring his valuable and relevant skill set into our organization," commented Joe Burnett, President and CEO at ClearPoint Neuro. "Our pharma and device partners in many ways view ClearP

    9/20/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Mary McNamara-Cullinane as Vice President of Regulatory Affairs

    SOLANA BEACH, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mary McNamara-Cullinane has joined the Company as Vice President of Regulatory Affairs. Ms. McNamara-Cullinane will report directly to Joe Burnett, ClearPoint Neuro's Chief Executive Officer, and serve as a member of the Company's senior leadership team. "We are thrilled to welcome Mary to our team as we fully expect her leadership and experience in Regulatory Affairs will contribute immediately to our partners and to patients globally," commented Joe Burnett, Presiden

    8/8/22 4:05:00 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

    SOLANA BEACH, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company's Board of Directors effective immediately. Ms. Fallon will also become a member of the Company's Audit Committee. Ms. Fallon is the Executive Vice President, HR/Legal, General Counsel and Secretary of Axcelis Technologies, Inc. (NASDAQ:ACLS), a provider of equipment and service solutions for the semiconductor manufacturing industry, with locations in eight countries. Ms. Fallon has held her current position sin

    7/15/21 4:30:00 PM ET
    $CLPT
    $ACLS
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Technology

    $CLPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/12/24 2:35:26 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/8/24 4:33:36 PM ET
    $CLPT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ClearPoint Neuro Inc.

    SC 13G/A - ClearPoint Neuro, Inc. (0001285550) (Subject)

    11/4/24 11:28:38 AM ET
    $CLPT
    Medical/Dental Instruments
    Health Care